AI
LGND icon

Axiom Investors’s Ligand Pharmaceuticals LGND Stock Holding History

Axiom Investors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-44,047
Closed -$3.73M – 133
2018
Q4 		$3.73M Buy
44,047
+4,049
+10% +$432K 0.13% 84
2018
Q3 		$6.85M Buy
39,998
+5,429
+16% +$818K 0.2% 71
2018
Q2 		$4.47M Buy
34,569
+319
+0.9% +$35.6K 0.13% 92
2018
Q1 		$3.53M Buy
+34,250
New +$3.39M 0.09% 110
2016
Q4 		– Sell
-19,908
Closed -$1.27M – 158
2016
Q3 		$1.27M Sell
19,908
-51,866
-72% -$3.81M 0.04% 108
2016
Q2 		$5.34M Buy
71,774
+652
+0.9% +$48.4K 0.15% 68
2016
Q1 		$4.75M Buy
71,122
+27,995
+65% +$1.7M 0.15% 66
2015
Q4 		$2.92M Buy
+43,127
New +$2.66M 0.09% 88
2014
Q3 		– Sell
-24,366
Closed -$947K – 168
2014
Q2 		$947K Sell
24,366
-35,105
-59% -$1.42M 0.02% 141
2014
Q1 		$2.5M Sell
59,471
-4,431
-7% -$185K 0.06% 100
2013
Q4 		$2.1M Buy
63,902
+7,316
+13% +$238K 0.06% 105
2013
Q3 		$1.53M Buy
+56,586
New +$1.59M 0.05% 110

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Axiom Investors's LGND Position: Q1 2019 in Review

Axiom Investors sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 44,047 shares — an estimated $3.73M sold.

Axiom Investors first reported a position in LGND in Q3 2013 and held it in 12 quarters. The position peaked at $6.85M in Q3 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Axiom Investors reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Axiom Investors sold 44,047 Ligand Pharmaceuticals shares in Q1 2019, an estimated $3.73M.
  • Axiom Investors first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 12 quarters.
  • Axiom Investors's Ligand Pharmaceuticals position peaked at $6.85M in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Axiom Investors's 13F filing for Q1 2019, filed 13 May 2019.